Loading patent…
AssigneesThe United States of America, as represented by the Secretay, Deparment of Health and human Servi, Institute for Research in Biomedicine
InventorsBaoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
Estimating the term…
Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
An isolated nucleic acid molecule encoding a recombinant human parainfluenza virus 1 (hPIV1) F ectodomain comprising amino acid substitutions that stabilize a trimer of the recombinant hPIV1 ectodomain in a prefusion conformation, wherein the amino acid substitutions comprise A466I and S473I cavity filling substitutions, wherein the amino acid numbering is according to a reference hPIV1 F sequence set forth as SEQ ID NO:
Dependencies are inferred from the claim text.